OSI Systems, Inc. Form 10-Q Summary
Business context and reporting period
OSI Systems designs and manufactures specialized electronic systems and components and provides security screening services across Security, Healthcare, and Optoelectronics and Manufacturing divisions. The filing covers the three and six months ended December 31, 2012, the second quarter and first six months of fiscal 2013. Results are unaudited.
Financial performance and liquidity
| Metric | Three months ended Dec. 31, 2012 | Year-over-year change | Six months ended Dec. 31, 2012 | Year-over-year change |
|---|---|---|---|---|
| Net revenues | $194.0 million | Up 3% | $375.7 million | Up 8% |
| Gross profit | $70.1 million | Up 7% | $131.4 million | Up 11% |
| Gross margin | 36.1% | Up from 35.0% | 35.0% | Up from 34.0% |
| Operating income | $18.7 million | Up 2% | $28.8 million | Up 11% |
| Net income | $12.4 million | Up 1% | $18.8 million | Up 10% |
| Diluted EPS | $0.60 | Down from $0.61 | $0.91 | Up from $0.85 |
Six-month revenue growth was led by Security, up 8% to $174.8 million, and Optoelectronics and Manufacturing, up 14% to $93.2 million. Healthcare revenue increased 2% to $107.7 million for the six-month period, but declined 5% in the second quarter to $56.1 million. Services revenue increased to $81.8 million from $54.5 million for the six-month comparison, while product revenue was approximately flat.
Six-month operating cash flow was $62.8 million, compared with $12.5 million in the prior-year period. Investing cash outflow was $125.4 million, including $117.6 million of capital expenditures primarily related to the Mexican turnkey screening program and a new building. Financing cash inflow was $16.4 million. Cash and cash equivalents declined to $46.9 million from $91.5 million at June 30, 2012.
At December 31, 2012, working capital was $241.2 million. Total current assets were $446.6 million and total current liabilities were $205.3 million. Debt consisted of $15.0 million outstanding under the revolving facility, $10.8 million remaining on a building term loan, and other current debt, for total borrowings of approximately $28.5 million. The company had a $425 million revolving credit facility, subject to $182.2 million of letters of credit, leaving substantial committed capacity but reducing availability through those letters of credit.
Material changes versus the prior comparable period
- Revenue growth and favorable mix increased gross margin by approximately 110 basis points in the quarter and 100 basis points for the six-month period.
- Turnkey security screening services, including the Mexican government program, increased revenue and generally carry higher margins than product sales.
- Second-quarter Healthcare revenue declined because of lower European and Middle Eastern sales, including decreases in anesthesia and patient monitoring products.
- Operating expenses increased 8% in the quarter and 11% for the six-month period. The six-month increase included higher SG&A, R&D investment, and a $2.7 million impairment, restructuring, and other charge.
- Interest expense and other income, net, increased to $2.5 million for the six-month period from $1.5 million, primarily because of greater letters-of-credit utilization and new mortgage debt.
- Capital expenditures increased materially from $9.1 million to $117.6 million for the six-month comparison, causing cash to decline despite stronger operating cash flow.
- The company repurchased shares and settled equity-plan tax obligations using $12.3 million of cash during the six months, compared with $1.8 million in the prior-year period.
Outlook, commentary, risks, contingencies, and unusual items
Management did not provide specific quantitative earnings or revenue guidance in the filing. Management expects continued opportunities in international security markets and turnkey screening, but cautions that healthcare customers may delay purchases because of economic uncertainty. The company also identifies international regulatory, geopolitical, currency, collection, distributor, and tariff risks.
In November 2012, the company received a TSA show-cause letter concerning the Rapiscan Secure 1000SP system and related ATR software. The company agreed to assist with redeployment of units previously sold to TSA and cease ATR software development. It recorded $2.7 million of impairment and other charges. The TSA agreement was not a final resolution because DHS disposition remained pending, and the company had not sold these systems to TSA in fiscal 2012 or fiscal 2013.
The company received a $100 million advance from the Mexican government for a turnkey security screening project and must provide a guarantee until the advance is earned. Contingent acquisition payments could total up to $63 million, with $18.8 million recorded as a liability at December 31, 2012. Ordinary-course legal proceedings were not considered likely to have a material adverse effect, although an unfavorable resolution could be material. The company also disclosed unaccrued environmental contamination at its Hawthorne facility that could become material if an adverse action is taken.
Foreign currency forward contracts of approximately $6.2 million and an interest-rate swap related to the building term loan were outstanding at period-end. A 10% appreciation or depreciation of the U.S. dollar relative to local currencies was estimated to change second-quarter operating income by approximately $2 million in the favorable or unfavorable direction, respectively. Management reported effective disclosure controls and no material changes to internal control over financial reporting.
Important facts for investors to verify
- Whether the Mexican turnkey screening program reaches planned execution milestones and converts the $100 million customer advance into recognized revenue and cash flow.
- The final DHS disposition and any additional financial, contractual, or reputational consequences related to the TSA Secure 1000SP and ATR matter.
- Whether the sharp increase in capital expenditures generates the expected operating returns and whether liquidity remains adequate as cash balances have declined.
- The availability under the revolving credit facility after accounting for $182.2 million of letters of credit and compliance with financial covenants.
- The trajectory of Healthcare demand, particularly in Europe and the Middle East, and the sustainability of higher margins from turnkey services.
- The timing and amount of contingent acquisition payments, royalty obligations, legal matters, and environmental remediation exposure.